7 / 33
Page 61
Notes:
conferenceseries
.com
Volume 7, Issue 6 (Suppl)
J Alzheimers Dis Parkinsonism, an open access journal
ISSN: 2161-0460
Dementia 2017
October 16-18, 2017
ALZHEIMER’S DISEASE & DEMENTIA
October 16-18, 2017 | Rome, Italy
9
th
International Conference on
Beneficial interaction between B vitamins and omega-3 fatty acids in slowing brain atrophy and
cognitive decline in subjects with Mild Cognitive Impairment (MCI)
1
A Oulhaj,
2
F Jernerén,
3
CA de Jager,
4
H Refsum
and
2
AD Smith
1
United Arab Emirates University, UAE
2
University of Oxford, UK
3
University of Cape Town, South Africa
4
University of Oslo, Norway
Introduction:
Raised plasma homocysteine (tHcy) and low intake of omega-3 long chain fatty acids (FA) are risk factors
for Alzheimer’s disease (AD). In subjects with MCI the VITACOG trial showed that B-vitamin treatment reduced the brain
atrophy rate and slowed cognitive decline. We now show that these effects of B-vitamins are influenced by baseline plasma
omega-3 FA concentrations.
Method:
The effects of B vitamin intervention in VITACOG subjects was analysed according to baseline omega-3 FA (DHA
and EPA) concentrations.
Results:
There was a significant interaction (P = 0.024) between B-vitamin treatment and plasma omega-3 FA on brain atrophy
rates. In subjects with high omega-3 FA, B-vitamin treatment slowed the atrophy rate by 40% compared with placebo, whereas
B-vitamins had no effect on atrophy in subjects with low omega-3 FA. A similar interaction was found between omega-3 FA
and the beneficial cognitive effects of B-vitamin treatment: high baseline omega-3 FA levels enhanced the slowing of cognitive
decline following B-vitamin treatment.
Conclusion:
The beneficial effect of B-vitamin treatment on brain atrophy and cognition was found only in subjects with high
plasma omega-3 FA. The results highlight the importance of identifying subgroups likely to benefit in clinical trials. A clinical
trial is needed to see if a combination of B-vitamins and omega-3 FA will slow conversion from MCI to AD.
aoulhaj@uaeu.ac.aeA Oulhaj et al., J Alzheimers Dis Parkinsonism 2017, 7:6(Suppl)
DOI: 10.4172/2161-0460-C1-034